Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 195-202

  Komiya, Akira ^a   Kato, Tomonori ^a   Hori, Takashi ^b   Fukuoka, Junya ^c   Yasuda, Kenji ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOYAMA UNIVERSITY HOSPITAL   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Immunohistochemical staining; Molecular marker; Prostate cancer; Spiral array; Tissue array

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

AGED; ARTICLE; CANCER PATIENT; CANCER RESEARCH; CANCER SPECIFIC SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSLATIONAL RESEARCH;

AGED; BIOPSY, NEEDLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891948736     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2173     Document Type: Article

References (27)

1. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
2. Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662, 2001.
3. Braunschweig T, Chung JY and Hewitt SM: Perspectives in tissue microarrays. Comb Chem High Throughput Screen 7: 575-585, 2004.
4. Tsurutani J, Fukuoka J, Tsurutani H, et al: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306-314, 2006.
5. Fukuoka J, Dracheva T, Shih JH, et al: Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol 38: 276-283, 2007.
6. Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10: 4314-4324, 2004.
7. Tsuna M, Kageyama S, Fukuoka J, et al: Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res 29: 2547-2554, 2009.
8. Rubin MA: Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol 195: 80-86, 2001.
9. Rubin MA, Dunn R, Strawderman M and Pienta KJ: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26: 312-319, 2002.
10. Inoue T, Segawa T, Shiraishi T, et al: Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66: 332-337, 2005.
11. Yasuda K, Komiya A, Watanabe A, et al: Expression of hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer. Anticancer Res 33: 575-581, 2013.
12. Komiya A, Yasuda K, Nozaki T, Fujiuchi Y, Hayashi S and Fuse H: Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma. Oncol Lett 5: 53-56, 2013.
13. Komiya A, Yasuda K, Watanabe A, Fujiuchi Y, Tsuzuki T and Fuse H: The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Mol Clin Oncol 1: 257-262, 2013.
14. Fukuoka J, Hofer MD, Hori T, et al: Spiral array: a new high-throughput technology covers tissue heterogeneity. Arch Pathol Lab Med 136: 1377-1384, 2012.
15. Zellweger T, Gunther S, Zlobec I, et al: Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 124: 2116-2123, 2009.
16. Miyake H, Muramaki M, Kurahashi T, Takenaka A and Fujisawa M: Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 28: 145-151, 2010.
17. Oxley JD, Winkler MH, Parry K, Brewster S, Abbott C and Gillatt DA: p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 89: 27-32, 2002.
18. Ecke TH, Schlechte HH, Schiemenz K, et al: TP53 gene mutations in prostate cancer progression. Anticancer Res 30: 1579-1586, 2010.
19. Nariculam J, Freeman A, Bott S, et al: Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl 11: 109-118, 2009.
20. Cho IC, Chung HS, Cho KS, et al: Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat 42: 157-162, 2010.
21. Fleischmann A, Huland H, Mirlacher M, et al: Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate 72: 991-997, 2012.
22. Abdollah F, Suardi N, Cozzarini C, et al: Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 63: 998-1008, 2013.
23. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ and Mason MD: Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev CD006019, 2006.
24. Chun FK, Steuber T, Erbersdobler A, et al: Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 49: 820-826, 2006.
25. Imamoto T, Utsumi T, Takano M, et al: Development and external validation of a nomogram predicting the probability of significant gleason sum ppgrading among Japanese patients with localized prostate cancer. Prostate Cancer 2011: 754382, 2011.
26. Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000.
27. Kyndi M, Sorensen FB, Knudsen H, et al: Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 47: 591-599, 2008.